Outcome studies show that GLP-1 medicines reduce rates of complications associated with T2D and/or obesity, including cardiovascular diseases, metabolic dysfunction–associated liver diseases, chronic kidney disease, osteoarthritis, and obstructive sleep apnea (Figure 1). Here, GCG is linked to chronic kidney disease.